In addition to FGFR1 overexpression, aberrant FGFR signaling in breast cancer may also include the amplification of FGFR1 and FGFR2, activation/mutations of FGFR2, increased secretion of FGF2, and other ligands from tumor microenvironment [4,10,40]. Here, FGF2 is linked to breast cancer.